Dr. Murray serves as a Gastroenterologist in the Division of Gastroenterology and Hepatology at the Mayo Clinic in Rochester, Minnesota. He founded a celiac disease clinic at the University of Iowa in 1992. In 1998, Dr. Murray joined the staff of Mayo clinic, where he runs the celiac disease research and clinical program that focuses on epidemiology, complications and mouse models of gluten sensitivity. In addition, Dr. Murray is a Professor of Medicine at the Mayo clinic in Rochester, Minnesota. He serves as a Consultant to several companies and has broad experience with clinical trials. Dr. Murray is an Associate Editor of Clinical Gastroenterology and Hepatology as well as an expert reviewer for many scientific journals. He has published over 100 scientific articles and has several patents on novel devices for the treatment of GI disorders. He has a large clinical practice widely focused on celiac disease and has been elected to the Best doctors in America from 2001 to 2006. He received his medical training in Ireland and GI training from the University of Iowa.
Dr. Kelly is a Professor of Medicine, Harvard Medical School, Chief of the Herrman L. Blumgart Internal Medicine Firm, Dir. of Gastroenterology Training and Medical Director of the Celiac Center at BIDMC He also heads clinical, research and educational programs in celiac disease as Medical Director of the Celiac Center at BIDMC. Dr. Kelly is the author of more than 150 clinical and basic research peer-reviewed publications. Dr. Kelly earned his doctor of medicine degree from Trinity College in Dublin, Ireland where he was a Foundation Scholar and recipient of numerous academic awards. Dr. Kelly has also received postgraduate clinical and research awards from the Crohn's and Colitis Foundation of America, the American Gastroenterological Association and the National Institutes of Health.
Dr. DiMarino is the William Rorer Professor of Medicine, Chief of the Division of Gastroenterology and Hepatology at Thomas Jefferson University Hospital, Director, Celiac Center. Dr. DiMarino is also founder of the first Adult Celiac Center in Philadelphia. Dr. DiMarino’s research interests have primarily been in the areas of esophageal, small intestinal motility, celiac disease and the safety of gastrointestinal endoscopy. Dr. DiMarino is the author of more than 300 original papers. He received his medical degree from Hahnemann Medical College and completed his internal medicine residency and fellowship in gastroenterology and served on the full-time faculty at the Hospital of the University of Pennsylvania.
Dr. Green is the Director of The celiac disease Center at Columbia University. He is a Professor of Clinical Medicine at the College of Physicians and Surgeons, Columbia University and Attending Physician at the New York-Presbyterian Hospital. Dr. Green received his medical degree from University of Sydney, Australia. After completing his Residency and GI fellowship in Sydney he became a Research fellow at Harvard Medical School and in the Gastroenterology Department at the Beth Israel Hospital in Boston. He is a Fellow of the Royal Australasian College of Physicians and the American College of Gastroenterology as well as a Member of the American Gastroenterologic Association and American Society of Gastrointestinal Endoscopy.
Celiac disease has been Dr. Green’s focus over the last 10 years with equal concentration on patient care and research. He is one of the few physicians in the United States with an intense clinical and academic interest and expertise in celiac disease. As a result of the need for a coordinated approach for the medical care of patients with celiac disease Dr. Green established the celiac disease Center at Columbia University. He is the author of the book celiac disease: A Hidden Epidemic. Dr. Green’s initial research involved studies of absorption of fats in the small intestine and the contribution of intestinal lipids to the lipids in the systemic circulation. His main clinical and research pursuits, over the last 12 years, have been in the clinical care and investigation of patients with celiac disease. As a result of his interest in this disease Dr. Green has cared for more than 500 patients with this condition. He has developed research programs with colleagues at Columbia University and other institutions into the epidemiology, genetics, diagnosis and management of celiac disease and its complications. In addition, he has lectured on celiac disease at many medical institutions throughout the United States as well as national and international meetings.
Dr. Mäki is professor (emeritus) at the University of Tampere and presently research director at the Tampere University Hospital, Tampere, Finland. He has an extensive track record in celiac disease research. Prof. Mäki’s research has been inspired by the needs of the celiac sufferers and he has been an active participant and advocate in the nationwide patient organization, also been the President of the Finnish Celiac Society. Lately professor Mäki has been involved in novel drug trials in celiac disease and his interest is especially in outcome measures. He is also a member of the Advisory Board in several companies focusing on celiac disease. Moreover, he has organized several international scientific celiac disease symposia. In 2010, Professor Mäki received the Wm. K. Warren Jr. Prize in celiac disease in Clinical/Translational Research, San Diego, USA. Mäki is a permanent member of the Finnish Academy of Science and Letters and the President of Finland has granted him the honor of Knight, First Class, of the Order of the White Rose of Finland in 2006.
Dr. Verdú is Associate Professor, Department of Medicine. Dr. Verdú became a faculty member at McMaster University in 2006, and her research focuses on the pathophysiology of inflammatory disorders such as IBD and celiac disease, with emphasis on diet-microbiota interactions. Dr. Verdú is the director of the Axenic Gnotobiotic Unit at McMaster University and holds a Canada Research Chair in Intestinal Inflammation, Microbiota, and Nutrition. She has received several research awards including the Canadian Celiac Association’s J.A. Campbell Research Award, Master’s in Gastroenterology by the American Gastroenterology Association and Young Investigator Award and Visiting Research Professor by the Canadian Gastroenterology Association. She is President of the North American Society for the Study of Celiac Disease. Dr. Verdú studied medicine at the University of Buenos Aires and completed a residency in Internal Medicine in Buenos Aires. During her residency, she lectured on Human Physiology at the University of Buenos Aires. She then obtained a fellowship from the Swiss National Foundation, moved to Lausanne, Switzerland, to work with Professor Andre Blum in clinical research. There, she studied the interaction between chronic infection with Helicobacter pylori and proton pump inhibitors on gastric acid secretion, bacterial overgrowth, and chronic gastritis in humans. During her Doctoral work in the Department of Gnotobiology and Microbiology at the Czech Academy of Science (working with Professor Helena Tlaskalova), she gained experience in animal models of inflammatory bowel disease (the most common and chronic inflammatory condition of the human bowel), intestinal microbiota, and gnotobiotic work. As a post-doctoral fellow at McMaster University, she worked on the role of probiotics in animal models of gut functional diseases.
Dr. Liddle is Professor of Medicine at Duke University Medical Center and former Chief of Division of Gastroenterology. At Duke, Dr. Liddle has held numerous leadership positions, most recently serving as Chief of the Gastroenterology Div. Dr. Liddle is an internationally recognized investigator in the physiology of the gastrointestinal tract. Dr. Liddle received his medical degree from Vanderbilt University and performed his internship and residency in Medicine at the University of California, San Francisco. He was a fellow in Gastroenterology at UCSF where he also performed his postdoctoral research training. Dr. Liddle has served on the faculties of UCSF & Duke Univ.
Dr. Sandborn is a board-certified gastroenterologist who is one of the world's top experts in the management of ulcerative colitis and Crohn’s disease. He directs the Inflammatory Bowel Disease (IBD) Center at UC San Diego Health. In addition, he is chief of the Division of Gastroenterology, vice chair of clinical operations for the Department of Medicine, and a member of the Clinical Practice Oversight (CPO) Board for UC San Diego Health. A professor in the Department of Medicine at UC San Diego School of Medicine, Dr. Sandborn conducts clinical trials in IBD and leads a team of physicians, research fellows, nurses, and study coordinators. With his physician collaborators, he evaluates and develops new diagnostic modalities and medical therapies for inflammatory bowel disease. Dr. Sandborn is internationally recognized for his contributions in the fields of biotechnology therapy, clinical pharmacology, conduct of clinical trials, diagnostic and treatment of pouchitis, epidemiology and natural history, and endoscopic and radiographic imaging techniques. His clinical trials have been instrumental to developing modern treatments for IBD. Dr. Sandborn has published nearly 600 articles in prestigious journals, including the New England Journal of Medicine, The Lancet, JAMA, the Annals of Internal Medicine, and Gastroenterology. Prior to joining UC San Diego Health, Dr. Sandborn worked in the Division of Gastroenterology and Hepatology at the Mayo Clinic in Rochester, Minn. Dr. Sandborn completed his fellowship at Mayo Clinic. He did his residency and earned his medical degree at Loma Linda University School of Medicine. He is board-certified in gastroenterology.
Dr. Feagan is a specialist in Internal Medicine, with training in clinical epidemiology and gastroenterology. His research interests focus on the design and implementation of randomized controlled trials of therapy for inflammatory bowel disease, and he has been the principal investigator on numerous multi-centre trials evaluating new treatments for the disease. Recently, Feagan began to investigate the application of cluster randomization in the evaluation of health policies. This methodology is well-suited to the assessment of the effectiveness of treatment programs, such as a care path for disease management. Dr. Feagan is a Professor of Medicine at the Schulich School of Medicine & Dentistry, a gastroenterologist at London Health Sciences Centre and Director of Robarts Clinical Trials at Robarts Research Institute.
Dr. Habtezion is an Associate Professor in the Division of Gastroenterology & Hepatology, and Immunology Program at Stanford University. Her lab is supported by the NIH and foundation grants focuses on mechanisms and immune responses in pancreatitis and inflammatory bowel disease. She is a member of NIH study section and Stanford Inflammatory Bowel Disease Program. She received B.Sc. in Chemistry from the University of Alberta, M.Sc. in Nutritional Biochemistry from the University of Guelph, and M.D. from McMaster University in Canada. She completed her Internal Medicine training at the University of Western Ontario, and her Gastroenterology & Hepatology fellowship at the University of Toronto. Following completion of her clinical training.
Dr. Lipkin is a board certified Medical Geneticist with a focus on genetic testing for gastrointestinal diseases, including the Lynch Syndrome, Familial Adenomatous Polyposis, Hemochromatosis and Hereditary Pancreatic Cancer among others. He is an authority on cancer genetic syndromes, with a particular emphasis on hereditary Gastrointestinal cancer syndromes. He is the author of MAPP-MMR, a bioinformatics program that is used to interpret whether Lynch syndrome missense variants are deleterious mutations or benign polymorphisms. He practices at Weill Medical College of Cornell University and New York-Presbyterian Hospital. He trained in Internal Medicine at Duke University and Medical Genetics at the National Human Genome Research Institute.
Dr. Ette has more than 26 years of broad experience in academia, drug evaluation and regulation, and the pharmaceutical industry. He has a Ph.D. in Clinical Pharmacology, an MBA, an M.S. in pharmacology, a B.S. in pharmacology, and a B.S. in pharmacy. A prolific author of several original articles in peer-reviewed journals, book chapters, numerous conference presentations and proceedings, Dr. Ette is on the editorial board of many clinical pharmacology / pharmacy journals as well as a referee for many biomedical journals. He is primary the editor of the classic pharmacometrics reference text, Pharmacometrics: the Science of Quantitative Pharmacology. He is also an invited speaker at many international clinical pharmacology/ pharmacy, pharmaceutical science, and statistical meetings.
Dr. Ette is a fellow of the American Colleges of Clinical Pharmacology and Clinical Pharmacy. He is the 2006, recipient of the American College of Clinical Pharmacy’s Therapeutic Frontier Lecture Award for distinguished scientists. He was a consultant to FDA from 1998 to 2001. In 1999, he was the recipient of the American College of Clinical Pharmacy’s prestigious Russell Miller Award for outstanding contributions to the clinical pharmacy literature; and in 1996 the recipient of Excellence in Review Science Award in CDER (FDA). At the FDA he was the major author of the Guidance for Industry: Population Pharmacokinetics.
He is an adjunct professor of applied pharmaceutical sciences at the University of Rhode Island’s College of Pharmacy and the University of the Pacific’s Thomas J. Long School of Pharmacy and Allied Health Sciences. Before now, he was the Senior Director/Head, Clinical Pharmacology, Vertex Pharmaceuticals, Cambridge, MA. where he introduced and championed efforts in the integration of knowledge-based (pharmacometric modeling and simulation) principles into drug development. Before taking up appointment at Vertex he was a leading pharmocometrician in the Office of Clinical Pharmacology, Center for Drug Evaluation and Research (CDER) at the Food and Drug Administration (FDA). He has broad experience academia, drug evaluation and regulation, and the pharmaceutical industry. Moreover, he has broad experience in the evaluation and development of drugs. He is a holder of patents.